These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1058 related articles for article (PubMed ID: 34530847)

  • 1. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optic neuritis in neuromyelitis optica.
    Levin MH; Bennett JL; Verkman AS
    Prog Retin Eye Res; 2013 Sep; 36():159-71. PubMed ID: 23545439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the long-term treatment of neuromyelitis optica spectrum disorder.
    Anderson M; Levy M
    J Cent Nerv Syst Dis; 2024; 16():11795735241231094. PubMed ID: 38312734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
    Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
    Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
    Valencia-Sanchez C; Wingerchuk DM
    BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and Safety of Inebilizumab, an Anti-CD19 Monoclonal Antibody, for the Treatment of Neuromyelitis Optica Spectrum Disorder: Based on the N-MOmentum Trial].
    Fujihara K; Sato H
    Brain Nerve; 2024 Oct; 76(10):1153-1160. PubMed ID: 39370840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromyelitis Optica (Devic's Syndrome): an Appraisal.
    Crout TM; Parks LP; Majithia V
    Curr Rheumatol Rep; 2016 Aug; 18(8):54. PubMed ID: 27402111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of neuromyelitis optica].
    Fujihara K
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(2):129-35. PubMed ID: 22576570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Nie T; Blair HA
    CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.
    Pittock SJ; Zekeridou A; Weinshenker BG
    Nat Rev Neurol; 2021 Dec; 17(12):759-773. PubMed ID: 34711906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
    N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
    Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
    J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapeutic targets for neuromyelitis optica spectrum disorder.
    Tradtrantip L; Asavapanumas N; Verkman AS
    Expert Opin Ther Targets; 2020 Mar; 24(3):219-229. PubMed ID: 32070155
    [No Abstract]   [Full Text] [Related]  

  • 17. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link.
    Jarius S; Wildemann B
    Med Hypotheses; 2013 Dec; 81(6):1090-5. PubMed ID: 24182872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
    J Tullman M; Zabeti A; Vuocolo S; Dinh Q
    Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
    Takai Y; Misu T; Suzuki H; Takahashi T; Okada H; Tanaka S; Okita K; Sasou S; Watanabe M; Namatame C; Matsumoto Y; Ono H; Kaneko K; Nishiyama S; Kuroda H; Nakashima I; Lassmann H; Fujihara K; Itoyama Y; Aoki M
    Brain; 2021 Sep; 144(8):2401-2415. PubMed ID: 33711152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuromyelitis Optica Spectrum Disorder].
    Misu T
    Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.